HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $35.00 price objective on the stock.

Several other research firms have also recently issued reports on ATYR. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Price Performance

ATYR stock opened at $3.27 on Monday. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.40. The stock has a market cap of $291.04 million, a PE ratio of -3.48 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. Equities research analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Atyr PHARMA

Several large investors have recently modified their holdings of ATYR. JPMorgan Chase & Co. raised its holdings in shares of Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $170,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $36,000. D.A. Davidson & CO. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $144,000. Institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.